Literature DB >> 31606335

Thymoma and pure red cell aplasia with hypoplasia of megakaryocytopoiesis: A rare and life-treating condition.

Giorgio Lo Iacono1, Federica Gigli2, Lorenzo Gherzi3, Daniele Avenoso2, Stefano Fiori4, Giulia Sedda3, Corrado Tarella5, Lorenzo Spaggiari6.   

Abstract

Thymic tumors are rare diseases with an incidence of 0.15 cases per 100,000 person-years. They can be associated with a variety of other syndromes, such as Myasthenia Gravis or autoimmune disorders. Among them, pure red cell aplasia is a hemato-pathological condition characterized by anemia, reticulocytopenia and erythroid cell hypoplasia of bone marrow. Here, we reported a case of a 62-year-old female with a long history of neurologic symptoms due to Myasthenia Gravis. She was diagnosed with thymoma, with mediastinal mass and pleural thickening. After chemoradiotherapy treatment, she was surgically resected successfully, but she developed anemia and severe thrombocytopenia, worsening in respiratory failure requiring intubation. A bone marrow biopsy was performed resulting in a red-cell aplasia with marked hypoplasia of megakaryocytopoiesis compatible with pure red cell aplasia with acquired thrombocytopenia. Considering that there are no standard treatments, clinical condition improvement was achieved only after some lines of medical treatment. Our data, together with the few already published, help to raise the attention towards acquired cytopenias and the need to optimize the treatment for a potentially life-threatening condition.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amegakaryocytic thrombocytopenia; Pure red cell aplasia; Thymoma

Mesh:

Year:  2019        PMID: 31606335     DOI: 10.1016/j.transci.2019.09.009

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  1 in total

1.  Clinical efficacy of thoracoscopic surgery by subxiphoid approach for thymoma and its influence on intraoperative blood loss and postoperative complications.

Authors:  Peng Shen; Quan Chen; Fengwei Zhu; Shouqi Tang; Xuxian Zhang; Feng Li
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.